[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100442830":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":32,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":80,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"German Diabetes Center","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort with type 1 diabetes (T1D) and type 2 diabetes (T2D)",null,"Prospectively followed cohort of people with new onset of ST-segment elevation myocardial infarction and diabetes mellitus (type 1 or type 2) according to the American Diabetes Association (ADA) and German Diabetes Society (DDG) criteria (HbA1c ≥6.5% or pathological oral glucose tolerance test (OGTT)), aged 18-80 years at inclusion into the study",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort of normal glucose tolerant people (NGT)","Prospectively followed cohort of healthy people with new onset of ST-elevation myocardial infarction and normal glucose tolerance status (HbA1c \\\u003C5.7% and normal OGTT), aged 18-80 years at inclusion into the study",{"label":16,"type":10,"description":17,"interventionNames":10},"Cohort of people with impaired glucose metabolism (IGM)","Prospectively followed cohort of people with new onset of ST-elevation myocardial infarction and impaired glucose metabolism, usually called prediabetes including impaired fasting glucose (IFG) and\u002For impaired glucose tolerance (IGT) and\u002For HbA1c 5.7-6.4%, aged 18-80 years at inclusion into the study",[19],{"name":20,"affiliation":5,"role":21},"Michael Roden, Prof., MD","PRINCIPAL_INVESTIGATOR",[23,28],{"name":20,"role":24,"phone":25,"phoneExt":26,"email":27},"CONTACT","+49-211-3382-0","201","michael.roden@ddz.de",{"name":29,"role":24,"phone":25,"phoneExt":30,"email":31},"Clara Möser, MD","318","clara.moeser@ddz.de",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Düsseldorf","North Rhine-Westphalia","40225","Germany","DE",{"type":41,"coordinates":42},"Point",[43,44],6.77927,51.22319,{"lat":44,"lon":43},[47,51,52,55],{"name":48,"role":24,"phone":25,"phoneExt":49,"email":50},"Clinical Study Center","209","studienzentrum@ddz.de",{"name":20,"role":21,"phone":10,"phoneExt":10,"email":10},{"name":53,"role":54,"phone":10,"phoneExt":10,"email":10},"Oana-Patricia Zaharia, Dr., MD","SUB_INVESTIGATOR",{"name":29,"role":54,"phone":10,"phoneExt":10,"email":10},{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100442830","metabolic-phenotyping-and-follow-up-of-patients-with-and-without-diabetes-after-new-onset-of-stemi-100442830",false,"NCT05046483","Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI","Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes Mellitus After New Onset of ST-Segment Elevation Myocardial Infarction (STEMI) (DISTEMI Study)","DISTEMI","Inclusion Criteria:\n\n* Condition after new onset of ST-segment elevation myocardial infarction (STEMI)\n* Age 18-80 years\n* HbA1c \\\u003C9.0%\n* People with diagnosis of diabetes mellitus according to ADA and DDG criteria (i.e. HbA1c ≥6.5% and\u002For pathological oral glucose tolerance test)\n* Healthy people with normal glucose tolerance status according to ADA and DDG criteria (i.e. HbA1c \\\u003C5.7% and normal OGTT)\n* People with impaired glucose metabolism (\"prediabetes\") according to ADA and DDG criteria (i.e. impaired fasting glucose and\u002For impaired glucose tolerance and\u002For HbA1c 5.7-6.4%)\n* Consent-able, hemodynamically stable people, without sedation (e.g. opiates) or other interfering medication (e.g. catecholamines)\n\nExclusion Criteria:\n\n* Diabetes mellitus category 3 A-H (ADA criteria), gestational diabetes\n* Current pregnancy\n* Infectious diseases, acute infections \u002F fever\n* Immunosuppressive therapy\n* Severe chronic renal, liver or heart disease (e.g. serum creatinin ≥1.6 mg\u002Fdl, peripheral artery occlusive disease stage IV)\n* Malignant diseases\n* Severe chronic psychiatric illness or addiction\n* Participation in an intervention trial",true,"ALL","18 Years","80 Years",{"count":71,"type":72},300,"ESTIMATED","OBSERVATIONAL","The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to characterize in detail the clinical, metabolical, immunological and vascular phenotype, investigate the interplay between myocardial remodelling and the metabolic phenotype, monitor the progression of the disease and compare the phenotype of STEMI people with diabetes mellitus to people with prediabetes and glucose tolerant people.",[76,77,78,79],"ST-segment Elevation Myocardial Infarction (STEMI)","Diabetes Mellitus","Insulin Resistance","Non-Alcoholic Fatty Liver Disease",[81,82,83,84,85,86,87,88,89],"ST-segment elevation myocardial infarction","STEMI","Cardiovascular diseases","CVD","Diabetes mellitus","Normal glucose tolerance","Non-alcoholic fatty liver disease","NAFLD","Liver fibrosis","2023-08-17",{"date":92,"type":93},"2023-08-22","ACTUAL",{"date":95,"type":93},"2018-12-30",{"date":97,"type":72},"2029-12-30",{"name":5,"class":6},1]